Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Saxne

Showing results (101-110 of 113) with videos related to

Pageof 12
Sort By:
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|February 13, 1999
Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritisL A Joosten, M M Helsen, T Saxne, et al.
Osteoarthritis and Cartilage|August 15, 2009
Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical trainingS G Petersen, T Saxne, D Heinegard, et al.
Arthritis Research|November 1, 2000
Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritisL A Joosten, E Lubberts, M M Helsen, et al.
Lupus|April 20, 2017
Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccineJ Nagel, T Saxne, P Geborek, et al.
Annals of the Rheumatic Diseases|June 23, 2004
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanerceptN Feltelius, C M Fored, P Blomqvist, et al.
Annals of the Rheumatic Diseases|April 15, 2005
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsJ Askling, C M Fored, L Brandt, et al.
Osteoarthritis and Cartilage|May 31, 2006
Classification of osteoarthritis biomarkers: a proposed approachD C Bauer, D J Hunter, S B Abramson, et al.
Annals of the Rheumatic Diseases|May 10, 2008
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics RegisterJ Askling, E Baecklund, F Granath, et al.
Annals of the Rheumatic Diseases|April 22, 2005
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsJ Askling, C M Fored, E Baecklund, et al.
Annals of the Rheumatic Diseases|March 5, 2002
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationA A den Broeder, L A B Joosten, T Saxne, et al.
Pageof 12

Showing results (101-110 of 113) with videos related to

Sort By:
Pageof 12
Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]|February 13, 1999
Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritisL A Joosten, M M Helsen, T Saxne, et al.
Osteoarthritis and Cartilage|August 15, 2009
Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical trainingS G Petersen, T Saxne, D Heinegard, et al.
Arthritis Research|November 1, 2000
Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritisL A Joosten, E Lubberts, M M Helsen, et al.
Lupus|April 20, 2017
Treatment with belimumab in systemic lupus erythematosus does not impair antibody response to 13-valent pneumococcal conjugate vaccineJ Nagel, T Saxne, P Geborek, et al.
Annals of the Rheumatic Diseases|June 23, 2004
Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanerceptN Feltelius, C M Fored, P Blomqvist, et al.
Annals of the Rheumatic Diseases|April 15, 2005
Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsJ Askling, C M Fored, L Brandt, et al.
Osteoarthritis and Cartilage|May 31, 2006
Classification of osteoarthritis biomarkers: a proposed approachD C Bauer, D J Hunter, S B Abramson, et al.
Annals of the Rheumatic Diseases|May 10, 2008
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics RegisterJ Askling, E Baecklund, F Granath, et al.
Annals of the Rheumatic Diseases|April 22, 2005
Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonistsJ Askling, C M Fored, E Baecklund, et al.
Annals of the Rheumatic Diseases|March 5, 2002
Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activationA A den Broeder, L A B Joosten, T Saxne, et al.
Pageof 12